Royalty Report: Medical, bone marrow, cell therapy – Collection: 330905


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Medical
  • bone marrow
  • cell therapy
  • Cancer
  • Diagnostic
  • Tissue
  • Drugs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 330905

License Grant
Licensor, an affiliate of Licensee Chief Science Officer,  hereby grants to Licensee an exclusive license, subject to any rights of the government in the Territory for the Field of Use, with the right to sublicense, under the Patent Rights and Technology to research, develop, make, have made, use, sell and import the Product(s) and to practice the Process claimed in the Patent Rights.
License Property
U.S. Patent Application #13/819,154 – Bone Marrow Derived CD271 Precursor Cells For Cardiac Repair

Technology known as
Bone Marrow Derived CD271 Precursor Cells For Cardiac Repair
Bone Marrow Derived CD271 Precursor Cells For Cardiac Repair

Field of Use
CD271+ technology is a subpopulation of bone marrow-derived MSCs.

Field of Use shall mean any aging related diseases or indications including frailty, metabolic syndrome, loss of muscle due to aging or frailty, and neurocognitive disorders.

IPSCIO Record ID: 330906

License Grant
University hereby grants to Licensee and Licensee hereby accepts an exclusive license, subject to any rights of the government in the Territory for the Field of Use, with the right to sublicense, under the Technology Rights and an exclusive license to the technology developed as of the Effective Date by Joshua M. Hare, M.D., that is not encumbered by any third party rights, which in University’s sole discretion, Is necessary to practice the Technology Rights to research, develop, make, have made, use, sell and import the Product(s) and to practice the Process(es) described and/or claimed In the Technology Rights,
License Property
Technology Rights shall mean Cell Aging Frailty-related MSC technology specifically set forth in Agreement.
Field of Use
Field of Use shall mean all fields for aging-related frailty.
Aging Frailty is a common geriatric condition that disproportionately increases a patient’s risk for poor clinical outcomes due to disease and injury, and is widely believed by geriatricians to ultimately be treatable.  MSCs are biological entities obtained from living humans that can pose risks to the recipient.  MSC therapies require many manufacturing steps. Cells must be harvested from donor tissue, isolated, and expanded in cell culture to produce a sufficient number of cells for use. Each step carries risks for contamination by other cells, microbes, or adventitious agents. The transfer of cells into a recipient can also carry risks and complications associated with the procedure itself, and a recipient may reject the transplanted cells.

IPSCIO Record ID: 301243

License Grant
With the amendment, the Licensee obtained license for a certain patent.  

Under the Agreement, each party has an undivided joint ownership interest in all of the patents and other intellectual property rights for such Target-Selector technology,  The license is exclusive, worldwide, irrevocable, and sublicensable.

License Property
The original agreement related to Target-Selector technology.

The patent relates to reagents and kits where the sample types are tissue, whole blood, bone marrow, cerebrospinal fluid or derivatives of any of the foregoing.

Field of Use
The patent relates  vitro diagnostic kits, or IVDs as applied to the oncology field.

The field of use is oncology, all applications in the fields of oncology clinical testing and oncology diagnostics, including both laboratory developed tests and IVD tests as applied to the oncology field, and oncology basic and clinical research.

IPSCIO Record ID: 383557

License Grant
Licensor grants the Licensee of Japan an exclusive license in the Territory, with the right to grant sublicenses, under the Licensor Patents and Licensor Technology to develop, register and to obtain Product Registrations, use, make, have made, import, export, offer to sell, sell and have sold Products for use in the Field in the Territory.
License Property
Licensor is the owner of certain technology, including, but not limited to patents and know-how, relating to mesenchymal stem cells.

MSC shall mean human cells that are capable of differentiation into more than one mesenchymal lineage.

Product means any product or composition that contains MSC and/or any process or service performed with respect to recovery, expansion, maintenance, purification, storage, production, formulation or use of MSC.

The patents include
—  Monoclonal antibodies specific for marrow-derived mesenchymal cells;
—  Uses for non-autologus mesenchymal stem cells;
—  Osteoporosis bond regeneration;
—  Mesenchymal stem cells for prevention and treatment of immune responses in transplantation;
—  Mesenchymal stem cells as immunosuppressants;
—  Regulation of Hema topoietic stem cell  differentiation by the use of human mesenchymal stem cells;
—  Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation.

Field of Use
The Field means the use of MSC in or in conjunction with the treatment of hematological malignancies by the use of hematopoietic stem cells derived from peripheral blood, cord blood or bone marrow.

Hematologic malignancies are cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. There are three main types of hematologic malignancies leukemia, lymphoma and multiple myeloma.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.